Literature DB >> 18830694

Tamoxifen induces regression of estradiol-induced mammary cancer in the ACI.COP-Ept2 rat model.

Rachel L Ruhlen1, Dana M Willbrand, Cynthia L Besch-Williford, Lixin Ma, James D Shull, Edward R Sauter.   

Abstract

The ACI rat is a unique model of human breast cancer in that mammary cancers are induced by estrogen without carcinogens, irradiation, xenografts or transgenic manipulations. We sought to characterize mammary cancers in a congenic variant of the ACI rat, the ACI.COP-Ept2. All rats with estradiol implants developed mammary cancers in 5-7 months. Rats bearing estradiol-induced mammary cancers were treated with tamoxifen for three weeks. Tamoxifen reduced tumor mass, measured by magnetic resonance imaging, by 89%. Tumors expressed estrogen receptors (ER), progesterone receptor (PR), and Erbb2. ERalpha and PR were overexpressed in tumor compared to adjacent non-tumor mammary gland. Thus, this model is highly relevant to hormone responsive human breast cancers.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18830694      PMCID： PMC3324940          DOI： 10.1007/s10549-008-0169-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


  34 in total

1.  Ploidy differences between hormone- and chemical carcinogen-induced rat mammary neoplasms: comparison to invasive human ductal breast cancer.

Authors:  Jonathan J Li; Dan Papa; Marilyn F Davis; S John Weroha; C Marcelo Aldaz; Karam El-Bayoumy; Jodi Ballenger; Ossama Tawfik; Sara Antonia Li
Journal:  Mol Carcinog       Date:  2002-01       Impact factor: 4.784

2.  Dietary energy restriction inhibits estrogen-induced mammary, but not pituitary, tumorigenesis in the ACI rat.

Authors:  Djuana M E Harvell; Tracy E Strecker; Benjamin Xie; Karen L Pennington; Rodney D McComb; James D Shull
Journal:  Carcinogenesis       Date:  2002-01       Impact factor: 4.944

3.  Susceptibility to estrogen-induced mammary cancer segregates as an incompletely dominant phenotype in reciprocal crosses between the ACI and Copenhagen rat strains.

Authors:  J D Shull; K L Pennington; T M Reindl; M C Snyder; T E Strecker; T J Spady; M Tochacek; R D McComb
Journal:  Endocrinology       Date:  2001-12       Impact factor: 4.736

4.  Prevention of solely estrogen-induced mammary tumors in female aci rats by tamoxifen: evidence for estrogen receptor mediation.

Authors:  S A Li; S J Weroha; O Tawfik; J J Li
Journal:  J Endocrinol       Date:  2002-11       Impact factor: 4.286

5.  Estrogen-induced pituitary tumor development in the ACI rat not inhibited by dietary energy restriction.

Authors:  T J Spady; K L Pennington; R D McComb; D F Birt; J D Shull
Journal:  Mol Carcinog       Date:  1999-12       Impact factor: 4.784

6.  Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.

Authors:  J L Masferrer; K M Leahy; A T Koki; B S Zweifel; S L Settle; B M Woerner; D A Edwards; A G Flickinger; R J Moore; K Seibert
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

7.  Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.

Authors:  Ari Ristimäki; Anna Sivula; Johan Lundin; Mikael Lundin; Tiina Salminen; Caj Haglund; Heikki Joensuu; Jorma Isola
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

8.  MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model.

Authors:  Karl Turetschek; Anda Preda; Eugenia Floyd; David M Shames; Viktor Novikov; Timothy P L Roberts; Jeanette M Wood; Yanjun Fu; Wayne O Carter; Robert C Brasch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03       Impact factor: 9.236

9.  Tissue-specific actions of the Ept1, Ept2, Ept6, and Ept9 genetic determinants of responsiveness to estrogens in the female rat.

Authors:  Scott G Kurz; Kimberly K Hansen; Mac T McLaughlin; Vijay Shivaswamy; Beverly S Schaffer; Karen A Gould; Rodney D McComb; Jane L Meza; James D Shull
Journal:  Endocrinology       Date:  2008-04-17       Impact factor: 4.736

10.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272
View more
  13 in total

Review 1.  Influence of berry polyphenols on receptor signaling and cell-death pathways: implications for breast cancer prevention.

Authors:  Harini S Aiyer; Anni M Warri; Denzel R Woode; Leena Hilakivi-Clarke; Robert Clarke
Journal:  J Agric Food Chem       Date:  2012-02-22       Impact factor: 5.279

2.  Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis.

Authors:  Matthew M Gubin; Robert Calaluce; J Wade Davis; Joseph D Magee; Connie S Strouse; Daniel P Shaw; Lixin Ma; Ashley Brown; Timothy Hoffman; Tammy L Rold; Ulus Atasoy
Journal:  Cell Cycle       Date:  2010-08-17       Impact factor: 4.534

3.  Berries and ellagic acid prevent estrogen-induced mammary tumorigenesis by modulating enzymes of estrogen metabolism.

Authors:  Harini S Aiyer; Ramesh C Gupta
Journal:  Cancer Prev Res (Phila)       Date:  2010-05-25

Review 4.  NO to breast: when, why and why not?

Authors:  Shehla Pervin; Gautam Chaudhuri; Rajan Singh
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

5.  Exposure to estrogen and ionizing radiation causes epigenetic dysregulation, activation of mitogen-activated protein kinase pathways, and genome instability in the mammary gland of ACI rats.

Authors:  Kristy Kutanzi; Olga Kovalchuk
Journal:  Cancer Biol Ther       Date:  2013-05-10       Impact factor: 4.742

Review 6.  Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.

Authors:  Priscilla A Furth; M Carla Cabrera; Edgar S Díaz-Cruz; Sarah Millman; Rebecca E Nakles
Journal:  Ann N Y Acad Sci       Date:  2011-07       Impact factor: 5.691

7.  Development and characterization of a novel rat model of estrogen-induced mammary cancer.

Authors:  Kirsten L Dennison; Nyssa Becker Samanas; Quincy Eckert Harenda; Maureen Peters Hickman; Nicole L Seiler; Lina Ding; James D Shull
Journal:  Endocr Relat Cancer       Date:  2015-04       Impact factor: 5.678

Review 8.  Induced mammary cancer in rat models: pathogenesis, genetics, and relevance to female breast cancer.

Authors:  James L Miller; Arianna P Bartlett; Rebecca M Harman; Prabin Dhangada Majhi; D Joseph Jerry; Gerlinde R Van de Walle
Journal:  J Mammary Gland Biol Neoplasia       Date:  2022-07-29       Impact factor: 2.698

9.  Mapping of three genetic determinants of susceptibility to estrogen-induced mammary cancer within the Emca8 locus on rat chromosome 5.

Authors:  Beverly S Schaffer; Kristin M Leland-Wavrin; Scott G Kurz; John A Colletti; Nicole L Seiler; Christopher L Warren; James D Shull
Journal:  Cancer Prev Res (Phila)       Date:  2012-11-14

Review 10.  Rat models of 17β-estradiol-induced mammary cancer reveal novel insights into breast cancer etiology and prevention.

Authors:  James D Shull; Kirsten L Dennison; Aaron C Chack; Amy Trentham-Dietz
Journal:  Physiol Genomics       Date:  2018-01-26       Impact factor: 3.107
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.